AGTII Liver Cancer Therapeutic Lentivirus, AG1103: Killing of Liver Tumor Cells In Vitro

Monolayers of liver cancer cells in culture were transfected with plasmid DNA corresponding to AG1103 therapeutic lentivirus; Control cells were not exposed to transfection agent or DNA, and Lipofectamine Control cells were exposed to transfection agent alone. Counts of viable cells in the treated cell cultures were normalized to counts of viable cells the viable in the Control Cell sample:

Observations: the viability of the AG1103-treated cell cultures ranged from 24% to 33% of that in the Control cell culture, indicating effective cell killing by the AG1103 vector design.

Monolayers of liver cancer cells in culture were exposed to AG1103 liver cancer therapeutic lentivirus for 8 hours or medium for 8 hours. Cell viability in the cultures was measured at 4 days and 7 days using MTS. Viability observed in the treated cell cultures was normalized to that of the untreated cell cultures:

Observations: Relative cell viability of the AG1103 therapeutic lentivirus treated cell cultures decrease to 36% of that in the Control cell cultures, indicating that infectious therapeutic virus retains the ability to kill liver cancer cells demonstrated with the plasmids above.

Observation of these AG1103-treated and untreated liver cancer cell cultures at day 6 revealed scattered viable cells in the AG1103-treated cultures (Treated) in contrast to healthy, nearly confluent cultures of cells in the untreated cultures (Untreated), confirming the MTS viability assessment:

Treated	Untreated